By Associate Professor Liz Caldon

Preprints

Caldon C; Alexandrou S; Lee C; Fernandez K; Wiharja C; Eshraghi L; Reeves J; Reed D; Portman N; Phan Z; Milioli H; Nikolic I; Cadell A; Croucher D; Simpson K; Lim E; Hickey T; Millar E; Alves C; Ditzel H, 2025, JNK pathway suppression drives resistance to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer, http://dx.doi.org/10.21203/rs.3.rs-5920749/v1

Phan Z; Fernandez K; Caldon E, 2025, Unmatched cell line collections are not optimal for identification of PARP inhibitor response and drug synergies, http://dx.doi.org/10.1101/2025.04.28.650908

Hosseinpour M; Malaver-Ortega L; Perlaza-Jimenez L; Joo J; Liu L; Caldon E; Dugué P-A; Dowty J; Southey M; Rosenbluh J, 2024, SAM-DNMT3A, a strategy for induction of genome-wide DNA methylation, identifies DNA methylation as a vulnerability in ER-positive breast cancers, http://dx.doi.org/10.1101/2024.01.16.575955

Phan Z; Ford C; Caldon E, 2023, DNA repair biomarkers to guide usage of combined PARP inhibitors and chemotherapy: a meta-analysis and systematic review, http://dx.doi.org/10.1101/2023.05.24.23290442

Tilley W; Hickey T; Selth L; Chia KM; Milioli H; Laven-Law G; Roden D; Jindal S; Hui M; Finlay-Schultz J; Ebrahimie E; Birrell S; Stelloo S; Iggo R; Alexandrou S; Caldon C; Abdel-Fatah T; Ellis I; Zwart W; Palmieri C; Sartorius C; Swarbrick A; Lim E; Carroll J, 2020, The Androgen Receptor is a Tumour Suppressor in Estrogen Receptor Positive Breast Cancer, http://dx.doi.org/10.21203/rs.3.rs-62718/v1

Aziz D; Portman N; Fernandez KJ; Lee C; Alexandrou S; Llop-Guevara A; Yong A; Wilkinson A; Sergio CM; Ferraro D; Etemadmoghadam D; Bowtell D; Investigators K; Serra V; Waring P; Lim E; Caldon CE, 2020, Cyclin E1 protein is stabilized inBRCA1mutated breast cancers leading to synergy between CDK2 and PARP inhibitors, http://dx.doi.org/10.1101/2020.01.29.911883

Portman N; Milioli H; Alexandrou S; Coulson R; Yong A; Fernandez K; Chia KM; Segara D; Parker A; Haupt S; Haupt Y; Tilley W; Swarbrick A; Caldon E; Lim E, 2020, MDM2 Inhibition in Combination with Endocrine Therapy and CDK4/6 Inhibition for the Treatment of ER-Positive Breast Cancer, http://dx.doi.org/10.1101/2020.06.09.140921

Du Q; Bert S; Armstrong N; Caldon E; Song J; Nair S; Gould C; Luu PL; Khoury A; Qu W; Zotenko E; Stirzaker C; Clark S, 2018, Replication timing shapes the cancer epigenome and the nature of chromosomal rearrangements, http://dx.doi.org/10.1101/251280

Back to profile page